Initially, it was planned to release 100 million doses; however, soon, the number of doses was reduced up to 50 million doses.
The reduction was explained by the fact that the enterprise lacks raw material due to the prolonged establishment of the supply chain.
“Scaling up a vaccine at this pace is unprecedented, and we have made significant progress, however, scale up of the raw material supply chain took longer than expected,” the company noted.
The company underlined that they are sure of the possibility to supply 1.3 billion doses until the end of 2021.
As we reported earlier, American biotech company Pfizer and German Biontech have applied for registration of their coronavirus vaccine in the United States.
The documents are submitted to the U.S. Food and Drug Administration (FDA). The concern has also sent applications for registration of the vaccine to other countries, including Australia, Great Britain, Europe, Canada, and Japan.
Besides, during the final stage of the trial of the vaccine against coronavirus infection developed by Pfizer and BioNTech, its efficacy was increased up to 94%.